Phytopharm Receives New ALS-Targeted Funding

While Phytopharm continues to develop its lead candidate Cogane for the treatment of neurodegenerative diseases, it has expanded its pharmaceutical scope to include an ALS program with funding support from the MNDA. The new program will focus on developing its P61 program, a series of novel chemical entities that exhibit anti-inflammatory activit y.

Click here to read more.

Share this: